Arterium Corporation announces project to help kidney disease patients

Arterium Corporation* has joined a cooperation project for extemporaneous preparation of neurology drugs to provide the Ukrainians suffering from chronic kidney disease with a product to relieve hyperkalemia. No medicinal product based on sodium polystyrene sulphonate as an active ingredient has been available in Ukraine thus far. However, according to the Ministry of Health, there are over 500,000 registered chronic kidney disease patients in the country. “Hyperkalemia is a potentially dangerous condition, wherein a patient develops an increased level of sodium in blood. If it gets too high, the outcome may be lethal,” Director for Endocrinology and Biotechnology Direction Valerii Vovcherenko explained, “Arterium Corporation is excited to join cooperation in the field of extemporaneous production and provide a quality substance for the drug that would tackle the problem”. Initially, on-demand preparation of the drug will be handled by Farmatsiya pharmacy chain. Arterium Corporation is planning to expand the extemporaneous production project to other pharmacies later.

*Arterium — Arterium Corporation itself and its parts OJSC Kievmedpreparat and OJSC Galychpharm. This information is intended for medical and pharmaceutical personnel only and shall be used only in relevant professional activities. The data given here is abridged. This website is a specialised publication intended for medical and pharmaceutical personnel only.